Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2022-12-06
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 77); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-18 (study day 145); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-09 (study day 197); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 242); relationship: N
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-06 (study day 409); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-04-13 (study day 476); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.